Multiple sclerosis

Exercise therapy for fatigue in multiple sclerosis

Abstract Background Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system affecting an estimated 1.3 million people worldwide. It is characterised by a variety of disabling symptoms of which excessive fatigue is the most frequent. Fatigue is often reported as the most invalidating symptom in people with MS. Various mechanisms directly and […]

Share

Pharmacological treatments for fatigue associated with palliative care

Abstract Background This review updates the original review, ‘Pharmacological treatments for fatigue associated with palliative care’ and also incorporates the review ‘Drug therapy for the management of cancer-related fatigue’. In healthy individuals, fatigue is a protective response to physical or mental stress, often relieved by rest. By contrast, in palliative care patients’ fatigue can be […]

Share

Dimethyl fumarate for multiple sclerosis

Abstract Background Multiple sclerosis (MS) often leads to severe neurological disability and a serious decline in quality of life. The ideal target of disease-modifying therapy for MS is to prevent disability worsening and improve quality of life. Dimethyl fumarate is considered to have an immunomodulatory activity and neuroprotective effect. It has been approved by the […]

Share

Telerehabilitation for persons with multiple sclerosis

Abstract Background Telerehabilitation, an emerging method, extends rehabilitative care beyond the hospital, and facilitates multifaceted, often psychotherapeutic approaches to modern management of patients using telecommunication technology at home or in the community. Although a wide range of telerehabilitation interventions are trialed in persons with multiple sclerosis (pwMS), evidence for their effectiveness is unclear. Objectives To […]

Share

Corticosteroids for treating optic neuritis

Abstract Background Optic neuritis is an inflammatory disease of the optic nerve. It usually presents with an abrupt loss of vision and recovery of vision is almost never complete. It occurs more commonly in women than in men. Closely linked in pathogenesis, optic neuritis may be the initial manifestation for multiple sclerosis. In some people, […]

Share

Biologics, colchicine, corticosteroids, immunosuppressants and interferon-alpha for Neuro-Behçet’s Syndrome

Abstract Background Neuro-Behçet Syndrome (NBS) is a severe chronic inflammatory vascular disease involving the Central Nervous System (CNS), and it is an invalidating condition with disability and a huge impact on quality of life. Recommendations on treatments for NBS include the use of disease-modifying therapies in general, although they are not supported by a systematic […]

Share

Interventions for the management of oral ulcers in Behçet’s disease

Abstract Background Behçet’s disease is a chronic inflammatory vasculitis that can affect multiple systems. Mucocutaneous involvement is common, as is the involvement of many other systems such as the central nervous system and skin. Behç̧et’s disease can cause significant morbidity, such as loss of sight, and can be life threatening. The frequency of oral ulceration […]

Share

Information provision for people with multiple sclerosis

Abstract Background People with multiple sclerosis (MS) are confronted with a number of important uncertainties concerning many aspects of the disease. Among others, these include diagnosis, prognosis, disease course, disease-modifying therapies, symptomatic therapies and non-pharmacological interventions. It has been shown that people with MS demand adequate information to be able to actively participate in medical […]

Share

Neuropsychological rehabilitation for multiple sclerosis

Abstract Background This is an update of the Cochrane review ‘Neuropsychological rehabilitation for multiple sclerosis’ (first published in The Cochrane Library2011, Issue 11). Cognitive deficits are a common manifestation of multiple sclerosis (MS) and have a significant effect on the patient’s quality of life. Alleviation of the harmful effects caused by these deficits should be […]

Share

Mycophenolate mofetil for relapsing-remitting multiple sclerosis

Abstract Background Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system and a leading cause of disability in young and middle-aged adults. Mycophenolate mofetil (MMF) is an immunosuppressive agent that has been used for the prevention of allograft rejection after renal, cardiac, or liver transplant and in patients with autoimmune diseases such […]

Share
  • The review abstracts published on this site are the property of John Wiley & Sons, Ltd., and of the Cochrane Review Groups that have produced the reviews.
Share
Share